Vertex Is The First To Get NaV1.8 To Proof Of Concept For Pain
Effort Is Built On Decades Of Sodium Channel Research
Executive Summary
Chief scientific officer David Altshuler talked to Scrip about the late-stage development plan for a drug that could represent a blockbuster-sized commercial opportunity, after two Phase II studies testing VX-548 met their primary endpoints.
You may also be interested in...
Vertex’s Non-Opioid Pain Candidate Hits Marks In Diabetic Peripheral Neuropathy
VX-548, which is set to read out Phase III data in acute pain in early 2024, demonstrated initial efficacy in chronic pain, but analysts say the drug will have to compete mainly on safety and tolerability.
Lilly Doubles Down On Novel Pain Drugs With Confo Therapeutics Deal
Belgium’s Confo Therapeutics gains its first big pharma partner in the field of non-opioid pain treatment, giving the big pharma will test its master protocol approach as it put its R&D muscle behind this major area of unmet need.
Vertex Readies For Commercial Future For Multi-Therapeutic Area R&D Strategy
Chief operating officer Stuart Arbuckle and chief scientific officer David Altshuler talked to Scrip about potential launches in sickle cell disease and pain, and the firm’s expanding pipeline.